Microdosing and drug development: past, present and future

Bibliography

• Garner RC. Accelerator mass spectrometry in pharmaceutical research and development–a new ultrasensitive analytical method for isotope measurement. Curr Drug Metab 2000;1(2):205-13
   PubMed Web of Science ®Google Scholar
• Lappin G, Garner RC. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov 2003;2(3):233-40
   PubMed Web of Science ®Google Scholar
• Lappin G, Garner RC. A review of human phase 0 and microdosing clinical trials following the US food and drug administration exploratory investigational new drug studies guidance. In J Pharm Med 2006;30(3):159-65
   Google Scholar
• Oosterhuis B. Trends in microdosing and other exploratory human pharmacokinetic studies for early drug development. Bioanalysis 2010;2(3):377-9
   PubMed Web of Science ®Google Scholar
• Boyd RA, Lalonde RL. Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact? Clin Pharmacol Ther 2007;81(1):24-6
   PubMed Web of Science ®Google Scholar
• Rowland M, Benet LZ, Lead PK. Commentary: phRMA PISC—prediction of human pharmacokinetics. J Pharm Sci 2011;100(10):4047-9
   PubMed Web of Science ®Google Scholar
• Kummar S, Kinders R, Gutierrez ME, et al. Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies. J Clin Oncol 2009;27(16):2705-11
   PubMed Web of Science ®Google Scholar
• ICH Topic M3 Note for Guidance on non-clinical safety pharmacology studies for human pharmaceuticals CPMP/ICH/286/95; 2009
   Google Scholar
• Bertino JS Jr, Greenberg HE, Reed MD. American college of clinical pharmacology position statement on the use of microdosing in the drug development process. J Clin Pharmacol 2007;47(4):418-22
   PubMed Web of Science ®Google Scholar
• Rowland M. Microdosing: a critical assessment of human data. J Pharm Sci 2012;101(11):4067-74
   PubMed Web of Science ®Google Scholar
• Yamane N, Igarashi A, Kusama M, et al. Cost-Effectiveness Analysis of Microdose Clinical Trials in Drug Development. Drug Metab Pharmacokinet 2013; In press Article ID: DMPK-12-RG-044
   PubMed Web of Science ®Google Scholar
• EMEA Position Paper on Non-clinical Safety Studies to Support Clinical Trials with a Single Microdose. CPMP/SWP/2599; 2004
   Google Scholar
• Food and Drug Administration US Department of Health and Human Services Guidance for Industry Investigators and Reviewers. Exploratory IND Studies (January 2006)
   Google Scholar
• Pharmaceutical and Medical Safety Bureau, Tokyo. Microdose clinical studies. Ministry of Health, Labor and Welfare, Japan; 2008
   Google Scholar
• Calvert AH, Plummer R. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials. Clin Cancer Res 2008;14(12):3664-9
   PubMed Web of Science ®Google Scholar
• Lappin G, Wagner C, Langer O, et al. New Ultrasensitive detection technologies and techniques for use in microdosing studies. Bioanalysis 2009;1(2):357-66
   PubMed Web of Science ®Google Scholar
• Wagner CC, Simpson M, Zeitlinger M, et al. A Combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil. Clin Pharmacokinet 2010;50(2):111-20
   Web of Science ®Google Scholar
• Wagner CC, Muller M, Lappin G, Langer O. Positron emission tomography for use in microdosing studies. Curr Opin Drug Discov Devel 2008;11(1):104-10
   PubMed Web of Science ®Google Scholar
• Sugiyama Y. Effective use of microdosing and Positron Emission Tomography (PET) studies on new drug discovery and development. Drug Metab Pharmacokinet 2009;24(2):127-9
   PubMed Web of Science ®Google Scholar
• Barker J, Garner RC. Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atom. Rapid Commun Mass Spectrom 1999;13(4):285-93
   PubMed Web of Science ®Google Scholar
• Salehpour M, Possnert G, Bryhni H. Subattomole sensitivity in biological accelerator mass spectrometry. Anal Chem 2008;80(10):3515-21
   PubMed Web of Science ®Google Scholar
• Comezoglu SN, Ly VT, Zhang D, et al. Biotransformation profiling of [(14)C]ixabepilone in human plasma, urine and feces samples using accelerator mass spectrometry (AMS). Drug Metab Pharmacokinet 2009;24(6):511-22
   PubMed Web of Science ®Google Scholar
• Ings R. Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge. Bioanalysis 2009;1(17):1293-305
   PubMed Web of Science ®Google Scholar
• Rowland M. Interview: interview with Professor Malcolm Rowland. Bioanalysis 2010;2(3):385-91
   PubMed Web of Science ®Google Scholar
• Lappin G, Rowland M, Garner RC. The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opin Drug Metab Toxicol 2006;2(3):419-27
   PubMed Web of Science ®Google Scholar
• Strong JM, Dutcher JS, Lee WK, Atkinson AJ Jr. Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method. Clin Pharmacol Ther 1975;18(5 Pt 1):613-22
   PubMed Web of Science ®Google Scholar
• Bae SK, Shon JH. Microdosing studies using accelerated mass spectrometry as exploratory investigational new drug trials. Arch Pharm Res 2011;34(11):1789-98
   PubMed Web of Science ®Google Scholar
• Gu H, Wang J, Aubry AF, et al. Calculation and mitigation of isotopic interferences in liquid chromatography-mass spectrometry/mass spectrometry assays and its application in supporting microdose absolute bioavailability studies. Anal Chem 2012;84(11):4844-50
   PubMed Web of Science ®Google Scholar
• Boddy AV, Sludden J, Griffin MJ, et al. Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia. Clin Cancer Res 2007;13(14):4164-9
   PubMed Web of Science ®Google Scholar
• Sparreboom A. Unexplored pharmacokinetic opportunities with microdosing in oncology. Clin Cancer Res 2007;13(14):4033-4
   PubMed Web of Science ®Google Scholar
• Lappin G, Kuhnz W, Jochemsen R, et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther 2006;80(3):203-15
   PubMed Web of Science ®Google Scholar
• Sarapa N, Hsyu PH, Lappin G, Garner RC. The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J Clin Pharmacol 2005;45(10):1198-205
   PubMed Web of Science ®Google Scholar
• Lappin G. Microdosing: current and the future. Bioanalysis 2010;2(3):509-17
   PubMed Web of Science ®Google Scholar
• The nobel prize in chemistry 1943 George de Hevesy. Available from: http://www.nobelprize.org/nobel_prizes/chemistry/laureates/1943/
   Google Scholar
• Ostenfeld T, Beaumont C, Bullman J, et al. Human microdose evaluation of the novel EP1 receptor antagonist GSK269984A. Br J Clin Pharmacol 2012;74(6):1033-44
   PubMed Web of Science ®Google Scholar
• Maeda K, Sugiyama Y. Novel strategies for microdose studies using non-radiolabeled compounds. Adv Drug Deliv Rev 2011;63532-8
   Google Scholar
• Sun L, Li H, Willson K, et al. Ultrasensitive Liquid Chromatography-Tandem Mass Spectrometric Methodologies for Quantification of Five HIV-1 Integrase Inhibitors in Plasma for a Microdose Clinical Trial. Anal Chem 2012;84(20):8614-21
   PubMed Web of Science ®Google Scholar
• Zhou XJ, Garner RC, Nicholson S, et al. Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects. J Clin Pharmacol 2009;49(12):1408-16
   PubMed Web of Science ®Google Scholar
• Yamane N, Tozuka Z, Kusama M, et al. Clinical relevance of liquid chromatography tandem mass spectrometry as an analytical method in microdose clinical studies. Pharm Res 2011;28(8):1963-72
   PubMed Web of Science ®Google Scholar
• Croft M, Keely B, Morris I, et al. Predicting drug candidate victims of drug-drug interactions, using microdosing. Clin Pharmacokinet 2012;51(4):237-46
   PubMed Web of Science ®Google Scholar
• Lappin G, Simpson M, Shishikura Y, Garner C. High-performance liquid chromatography accelerator mass spectrometry: correcting for losses during analysis by internal standardization. Anal Biochem 2008;37893-5
   Google Scholar
• Young G, Ellis WJ. AMS in drug development at GSK. Nucl Instruments Methods Phys Res 2007;B 259:752-7
   Google Scholar
• Affinium. Affinium Pharmaceuticals, Ltd. Announces first patient dosed with oral AFN-1252 in a phase 2 clinical trial for acute bacterial skin & skin structure infections. 2012. Available from: http://www.afnm.com/news/affinium-news-020112.htm
   Google Scholar
• Wang JL, Aston K, Limburg D, et al. The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part III: the three microdose candidates. Bioorg Med Chem Lett 2010;20(23):7164-8
   PubMed Web of Science ®Google Scholar
• Kuwano K, Hashino A, Asaki T, et al. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl) acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther 2007;322(3):1181-8
   PubMed Web of Science ®Google Scholar
• Lappin G, Garner C. The utility of microdosing over the past 5 years. Expert Opin Drug Metab Toxicol 2008;4(12):1499-506
   PubMed Web of Science ®Google Scholar
• Levy G, Mager DE, Cheung WK, Jusko WJ. Comparative pharmacokinetics of coumarin anticoagulants L: physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man. J Pharm Sci 2003;92(5):985-94
   PubMed Web of Science ®Google Scholar
• Lappin G, Shishikura Y, Jochemsen R, et al. Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers. Eur J Pharm Sci 2011;43:141-50
   PubMed Web of Science ®Google Scholar
• Tang H, Mayersohn M. A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry. J Pharm Sci 2006;95(8):1783-99
   PubMed Web of Science ®Google Scholar
• Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J 2011;13(4):519-47
   PubMed Web of Science ®Google Scholar
• Zhao P, Rowland M, Huang SM. Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin Pharmacol Ther 2012;92(1):17-20
   PubMed Web of Science ®Google Scholar
• Beaumont K, Smith DA. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research? Curr Opin Drug Discov Devel 2009;12(1):61-71
   PubMed Web of Science ®Google Scholar
• Jones RD, Jones HM, Rowland M, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. J Pharm Sci 2011;100(10):4074-89
   PubMed Web of Science ®Google Scholar
• Poulin P, Jones HM, Jones RD, et al.PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets. J Pharm Sci 2011;100(10):4050-73
   PubMed Web of Science ®Google Scholar
• Poulin P, Jones RD, Jones HM, et al. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. J Pharm Sci 2011;100(10):4127-57
   PubMed Web of Science ®Google Scholar
• Ring BJ, Chien JY, Adkison KK, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessment of prediction methods of human clearance. J Pharm Sci 2011;100(10):4090-110
   PubMed Web of Science ®Google Scholar
• Vuppugalla R, Marathe P, He H, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach. J Pharm Sci 2011;100(10):4111-26
   PubMed Web of Science ®Google Scholar
• Maeda K, Ikeda Y, Fujita T, et al. Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther 2011;90(4):575-81
   PubMed Web of Science ®Google Scholar
• Tachibana T, Kato M, Sugiyama Y. Prediction of nonlinear intestinal absorption of CYP3A4 and P-glycoprotein substrates from their in vitro Km values. Pharm Res 2012;29(3):651-68
   PubMed Web of Science ®Google Scholar
• Ieiri I, Doi Y, Maeda K, et al. Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose. J Clin Pharmacol 2011
   PubMed Web of Science ®Google Scholar
• Ieiri I, Fukae M, Maeda K, et al. Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing. Int J Clin Pharmacol Ther 2012;50(10):689-700
   PubMed Web of Science ®Google Scholar
• Turteltaub KW, Dingley KH, Curtis KD, et al. Macromolecular adduct formation and metabolism of heterocyclic amines in humans and rodents at low doses. Cancer Lett 1999;143(2):149-55
   PubMed Web of Science ®Google Scholar
• Turteltaub KW, Mauthe RJ, Dingley KH, et al. MeIQx-DNA adduct formation in rodent and human tissues at low doses. Mutat Res 1997;376(1-2):243-52
   PubMed Web of Science ®Google Scholar
• Lappin G, Warrington S, Honeybourne D, et al. Concentrations of AR-709 in plasma and key compartments of the lungs after microdosing. Paper presented at the Poster presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, USA; 2007
   Google Scholar
• Vuong LT, Ruckle JL, Blood AB, et al. Use of accelerator mass spectrometry to measure the pharmacokinetics and peripheral blood mononuclear cell concentrations of zidovudine. J Pharm Sci 2008;97(7):2833-43
   PubMed Web of Science ®Google Scholar
• Chen J, Flexner C, Liberman RG, et al. Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of Zidovudine triphosphate in a microdosing study. J Acquir Immune Defic Syndr 2012;61(5):593-9
   PubMed Web of Science ®Google Scholar
• Chen J, Garner RC, Lee LS, et al. Accelerator mass spectrometry measurement of intracellular concentrations of active drug metabolites in human target cells in vivo. Clin Pharmacol Ther 2010;88(6):796-800
   PubMed Web of Science ®Google Scholar
• Chen J, Seymour M, Lee L, et al. Accelerator Mass Spectrometry: A New Way to Measure Intracellular NRTI Triphosphates. 16th Conference on Retroviruses and Opportunistic Infections; San Francisco, USA; 2009
   Google Scholar
• Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992;65(2):287-91
   PubMed Web of Science ®Google Scholar
• Parlato C, Barbarisi M, Moraci M, Moraci A. Surgery, radiotherapy and temozolomide in treating high-grade gliomas. Front Biosci 2006;11:1280-3
   PubMed Web of Science ®Google Scholar
• Martin EA, Brown K, Gaskell M, et al. Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res 2003;63(23):8461-5
   PubMed Web of Science ®Google Scholar
• Vuong LT, Blood AB, Vogel JS, et al. Applications of accelerator MS in pediatric drug evaluation. Bioanalysis 2012;4(15):1871-82
   PubMed Web of Science ®Google Scholar
• Harrison A, Gardner I, Hay T, et al. Case studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigms. Xenobiotica 2012;42(1):57-74
   PubMed Web of Science ®Google Scholar
• FDA. Food and Drug Administration US Department of Health and Human Services Guidance for Industry Safety Testing of Drug Metabolites. 2008
   Google Scholar
• Garner RC. Less is more: the human microdosing concept. Drug Discov Today 2005;10(7):449-51
   PubMed Web of Science ®Google Scholar
• Chan E, McLachlan AJ, Pegg M, et al. Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol 1994;37(6):563-9
   PubMed Web of Science ®Google Scholar
• Garzone PD, Kroboth PD. Pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 1989;16(6):337-64
   PubMed Web of Science ®Google Scholar
• Lappin G, Shishikura Y, Jochemsen R, et al. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Pharm Sci 2010;40125-31
   Google Scholar
• Yamazaki A, Kumagai Y, Yamane N, et al. Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS. J Clin Pharm Ther 2010;35(2):169-75
   PubMed Web of Science ®Google Scholar
• Davey PG. The pharmacokinetics of clarithromycin and its 14-OH metabolite. J Hosp Infect 1991;19(Suppl A):29-37
   PubMedGoogle Scholar
• Fowler PA, Lacey LF, Thomas M, et al. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991;31(5):291-4
   PubMed Web of Science ®Google Scholar
• Hollmann M, Brode E, Hotz D, et al. Investigations on the pharmacokinetics of propafenone in man. Arzneimittelforschung 1983;33(5):763-70
   PubMed Web of Science ®Google Scholar
• Albert KS, Sedman AJ, Wilkinson P, et al. Bioavailability studies of acetaminophen and nitrofurantoin. J Clin Pharmacol 1974;14(5-6):264-70
   PubMed Web of Science ®Google Scholar
• Viswanathan CT, Booker HE, Welling PG. Pharmacokinetics of phenobarbital following single and repeated doses. J Clin Pharmacol 1979;19(5-6):282-9
   PubMed Web of Science ®Google Scholar
• Madan A, O'Brien Z, Wen J, et al. A pharmacokinetic evaluation of five H1 antagonists after an oral and intravenous microdose to human subjects. Br J Clin Pharmacol 2008;67(3):288-98
   Web of Science ®Google Scholar
• Zhou XJ, Pietropaolo K, Damphousse D, et al. Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects. Antimicrob Agents Chemother 2009;53(5):1739-46
   PubMed Web of Science ®Google Scholar
• Yamane N, Takami T, Tozuka Z, et al. Microdose clinical trial: quantitative determination of nicardipine and prediction of metabolites in human plasma. Drug Metab Pharmacokinet 2009;24(4):389-403
   PubMed Web of Science ®Google Scholar
• Fredholm BB, Battig K, Holmen J, et al. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999;51(1):83-133
   PubMed Web of Science ®Google Scholar
• Uchida S, Yamada H, Li XD, et al. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol 2006;46(11):1290-8
   PubMed Web of Science ®Google Scholar
• Ieiri I, Nishimura C, Maeda K, et al. Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose. Pharmacogenet Genomics 2011;21(8):495-505
   PubMed Web of Science ®Google Scholar
• Mahajan R, Parvez A, Gupta K. Microdose vs Therapeutic dose for evaluation of pharmacokinetic data: a comparative study. J Young Pharmacists 2009;28(1):290-4
   Google Scholar
• Kusuhara H, Ito S, Kumagai Y, et al. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 2011;89(6):837-44
   PubMed Web of Science ®Google Scholar
• Maeda K, Takano J, Ikeda Y, et al. Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study. Clin Pharmacol Ther 2011;90(2):263-70
   PubMed Web of Science ®Google Scholar
• Friedman H, Greenblatt DJ, Peters GR, et al. Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. Clin Pharmacol Ther 1992;52(2):139-50
   PubMed Web of Science ®Google Scholar
• Blyden GT, Greenblatt DJ, Scavone JM, Shader RI. Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration. J Clin Pharmacol 1986;26(7):529-33
   PubMed Web of Science ®Google Scholar
• Mclean MA, Tam C-Y, Baratta MT, et al. accelerating drug development: methodology to support first-in-man pharmacokinetic studies by the use of drug candidate microdosing. Drug Dev Res 2007;6814-22
   Google Scholar
• Ni J, Ouyang H, Aiello M, et al. Microdosing assessment to evaluate pharmacokinetics and drug metabolism in rats using liquid chromatography-tandem mass spectrometry. Pharm Res 2008;25(7):1572-82
   PubMed Web of Science ®Google Scholar
• Balani SK, Nagaraja NV, Qian MG, et al. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry. Drug Metab Dispos 2006;34(3):384-8
   PubMed Web of Science ®Google Scholar
• Sandhu P, Vogel JS, Rose MJ, et al. Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. Drug Metab Dispos 2004;32(11):1254-9
   PubMed Web of Science ®Google Scholar